SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-017827
Filing Date
2023-05-04
Accepted
2023-05-04 16:05:03
Documents
67
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q aldx-20230331.htm   iXBRL 10-Q 2055662
2 EX-31.1 aldx-ex31_1.htm EX-31 20890
3 EX-31.2 aldx-ex31_2.htm EX-31 21300
4 EX-32.1 aldx-ex32_1.htm EX-32 16060
  Complete submission text file 0000950170-23-017827.txt   6945510

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT aldx-20230331_def.xml EX-101.DEF 150849
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT aldx-20230331_lab.xml EX-101.LAB 387825
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT aldx-20230331.xsd EX-101.SCH 47410
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT aldx-20230331_cal.xml EX-101.CAL 41320
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT aldx-20230331_pre.xml EX-101.PRE 275596
61 EXTRACTED XBRL INSTANCE DOCUMENT aldx-20230331_htm.xml XML 1109520
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36332 | Film No.: 23888564
SIC: 2834 Pharmaceutical Preparations